Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Sir Mene Pangalos said the company was considering not submitting it to the FDA if it finds it is “banging its head against a brick wall indefinitely.”
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
AstraZeneca and Merck announced their Lynparza drug reduced the risk of death by 32% compared to placebo for specific breast cancer patients.
In his new book, Warp Speed, Paul Mango said the realization that many healthcare workers didn’t want the vaccine, for instance, was shocking.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biogen returned the rights to a dry age-related macular degeneration (dAMD) drug to Catalyst Biosciences. Biogen also ended the partnership regarding other dry AMD.
Healthcare giant Sanofi and cancer-focused biotech company Seagen Inc. announced an exclusive collaboration agreement to develop antibody-drug conjugates (ADCs) for cancer treatments.
In total, FSI XI has netted over $987 million in commitments to drive the success of Frazier’s ongoing investment strategy.
Robert Hollingsworth, PhD, a former Pfizer executive who oversaw the development of cancer vaccines and immunotherapeutics, has taken on the role of the CSO at Shoreline Biosciences.
The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates.